Eyeing a future of improved patient outcomes, the Medical College of Wisconsin is working to advance the prevention, ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...